The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of IMMU, PRGO, DXC and MU

February 4, 2019

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Immunomedics, Inc. (NASDAQ: IMMU) Class Period: August 23, 2018 to December 20, 2018 Lead Plaintiff Deadline: February 25, 2019

The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food & Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.

On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.

Get additional information about the IMMU lawsuit: http://www.kleinstocklaw.com/pslra-1/immunomedics-inc-loss-submission-form?wire=3

Perrigo Company plc (NYSE: PRGO) Class Period: November 8, 2018 to December 20, 2018 Lead Plaintiff Deadline: March 4, 2019

During the Class Period, and unbeknownst to investors, Perrigo misled investors by way of an SEC filing on November 8, 2018. On that date, Perrigo disclosed the existence of an audit finding letter from the Irish tax authorities without disclosing material details associated with the letter.

Get additional information about the PRGO lawsuit: http://www.kleinstocklaw.com/pslra-1/perrigo-company-plc-loss-submission-form?wire=3

DXC Technology Company (NYSE: DXC) Class Period: February 8, 2018 to November 6, 2018 Lead Plaintiff Deadline: February 25, 2019

During the class period, DXC Technology Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance during the Class Period was without a reasonable basis.

Get additional information about the DXC lawsuit: http://www.kleinstocklaw.com/pslra-1/dxc-technology-company-loss-submission-form?wire=3

Micron Technology Inc. (NASDAQGS: MU) Class Period: September 26, 2017 to November 19, 2018 Lead Plaintiff Deadline: March 25, 2019

The lawsuit alleges that Micron Technology Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company engaged in anti-competitive behavior, including artificially restricting supply growth of DRAM; (2) these anti-competitive efforts were reasonably likely to lead to regulatory scrutiny; (3) the Company’s anti-competitive efforts artificially boosted its operating metrics; (4) as a result, the Company’s financial performance, including revenue, was overstated; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the MU lawsuit: http://www.kleinstocklaw.com/pslra-1/micron-technology-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899Fax: (347) 558-9665 www.kleinstocklaw.com

Update hourly